Attached files
file | filename |
---|---|
8-K - FORM 8-K - Riot Blockchain, Inc. | appy_8k.htm |
EX-10.1 - EXHIBIT 10.1 - Riot Blockchain, Inc. | ex10x1.htm |
Exhibit 99.1
AspenBio
Continues to Strengthen Leadership Adding Steve Lundy as CEO
Daryl
Faulkner Remains in Leadership Role as Executive Chairman
CASTLE ROCK, CO., March 25,
2010 -- AspenBio Pharma,
Inc. (NASDAQ: APPY), reported that
Steve Lundy has joined the company as Chief Executive Officer and will become a
member of the Board of Directors. The addition of Mr. Lundy is part of
succession and organizational planning that was initiated in the latter half of
2009. Daryl Faulkner, who served as Interim CEO in 2009 will
relinquish that role but will continue as Executive Chairman of the company and
will focus more on strategic matters.
Mr. Lundy
brings over twenty years’ experience in the medical device and diagnostic
industry. He has successfully led the commercial launch of several novel
diagnostic assays including the first molecular test for Methicillin-resistant
Staphylococcus aureus. He has also been instrumental in transactions
involving the sale or merger of several diagnostic companies to larger life
sciences entities. Most recently Mr. Lundy served as CEO of
MicroPhage, Inc. Previously, he has held senior executive roles at
Vermillion, Inc. and GeneOhm which was acquired by Becton
Dickinson.
The
company recently reported completion of patient enrollment for its AppyScore™
pivotal clinical trial. AppyScore is the company’s blood test to help
evaluate patients suspected of having acute appendicitis. The company plans to
file a 510(k) application for AppyScore in the second quarter of
2010.
“This is
an important time in the life of the company as we are moving quickly towards
commercialization. The appointment of Steve Lundy follows an extensive executive
search, and I am truly pleased to have someone with Steve’s proven leadership
record and IVD experience driving the day-to-day execution of the company’s
objectives during this critical next phase in the company’s development,” stated
Daryl Faulkner, Executive Chairman of the Board.
Lundy
commented, “I am excited about AspenBio’s opportunities in both the diagnostic
and animal health development programs. My due diligence, including
discussions with AspenBio board members and industry thought leaders have
convinced me that AppyScore has the potential to make a major impact on patient
care. I believe the company has positioned itself with technology, an
intellectual property estate and a leadership team that are essential for
success and I am very enthused to be joining the company in this important
leadership role.”
About
AspenBio Pharma, Inc.
AspenBio
Pharma, Inc. (NASDAQ: APPY) is developing and commercializing innovative
products that address unmet diagnostic and therapeutic needs. The company’s lead
product candidate, AppyScore, is a novel, blood-based diagnostic test that
evaluates patients suspected of having acute appendicitis and addresses the
difficult challenge of properly diagnosing appendicitis in the hospital
emergency department setting. For more information, please visit
www.aspenbiopharma.com.
Forward-Looking
Statements
This news
release includes "forward-looking statements" of AspenBio Pharma, Inc. ("APPY")
as defined by the Securities and Exchange Commission ("SEC"). All statements,
other than statements of historical fact, included in the press release that
address activities, events or developments that APPY believes or anticipates
will or may occur in the future are forward-looking statements. These statements
are based on certain assumptions made based on experience, expected future
developments and other factors APPY believes are appropriate in the
circumstances. Such statements are subject to a number of assumptions, risks and
uncertainties, many of which are beyond the control of APPY. Investors are
cautioned that any such statements are not guarantees of future performance.
Actual results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including statements
regarding actual trial results, the ability to successfully complete the
clinical trial data assessments required for FDA submission, obtain FDA approval
for, cost effectively manufacture and generate revenues from the appendicitis
test and other new products, including its animal health drugs, execute
agreements required to successfully advance the company's objectives, retain the
scientific management team to advance the products, overcome adverse changes in
market conditions and the regulatory environment, fluctuations in sales volumes,
obtain and enforce intellectual property rights, and realization of intangible
assets. Furthermore, APPY does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this news release
should be considered in conjunction with the warnings and cautionary statements
contained in APPY's recent filings with the SEC.
For
more information contact:
AspenBio
Pharma, Inc.
Gregory
Pusey, Vice President and Vice Chairman
Tel
303-722-4008
Investor
Relations:
Liolios
Group, Inc.
Geoffrey
Plank or Ron Both
Tel
949-574-3860
# # # #